Actualités

Merck stock has almost doubled investors' money over the past five years, yet there is a clear split between valuation tools. A Discounted Cash Flow (DCF) estimate points to a sizeable gap to intrinsic value, while market based multiples suggest the shares are already pricing in a lot of optimism. Merck has returned 99.7% over five years, which puts recent gains in focus as investors weigh how much future growth is already reflected in the price. Ongoing investment in oncology and new...

Merck (MRK) is back in focus after a run of product and earnings headlines. Fresh approvals and label expansion efforts for KEYTRUDA and ENFLONSIA now sit alongside a raised 2026 revenue outlook and recent acquisition charges. See our latest analysis for Merck. Merck’s share price has moved to US$128.37 after a strong run, with a 90 day share price return of 15.25% and a 1 year total shareholder return of 65.06%, suggesting momentum has been building as approvals, trial readouts and raised...

Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]

Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely watched clinical trial of the year delivered a statistical miss that has prompted a wave of analyst downgrades. The company disclosed on Friday that its phase 3 trial of...

With an annual dividend yield of 3.06%, Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Blue Chip Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. On May 7, Citi analyst […]

With an upside potential of 21.26% as of May 3, Merck & Co., Inc. (NYSE:MRK) is included among the 10 Best Fortune 500 Stocks to Buy According to Analysts. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. […]

AMD upgraded, Reddit downgraded: Wall Street's top analyst calls